Oyster Point Pharma, Inc. (OYST) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
202 CARNEGIE CENTER PRINCETON, NJ 08540 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2022 MRQ | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 193,372 | 192,585 | 139,147 | |||
| Cash and cash equivalent | 193,372 | 192,585 | 139,147 | |||
| Restricted cash and investments | 61 | |||||
| Receivables | 6,656 | |||||
| Inventory, net of allowances, customer advances and progress billings | 6,086 | |||||
| Inventory | 6,086 | |||||
| Other undisclosed current assets | 9,075 | 3,782 | 3,033 | |||
| Total current assets: | 215,250 | 196,367 | 142,180 | |||
| Noncurrent Assets | ||||||
| Finance lease, right-of-use asset, after accumulated amortization | 18 | 34 | ||||
| Operating lease, right-of-use asset | 2,884 | 644 | 797 | |||
| Property, plant and equipment | 2,497 | 804 | 181 | |||
| Long-term investments and receivables | 886 | |||||
| Long-term investments | 886 | |||||
| Restricted cash and investments | 61 | 51 | ||||
| Other noncurrent assets | 1,082 | |||||
| Total noncurrent assets: | 7,367 | 1,543 | 1,029 | |||
| TOTAL ASSETS: | 222,617 | 197,910 | 143,209 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 28,007 | 10,564 | 5,103 | |||
| Accounts payable | 6,496 | 2,279 | 500 | |||
| Accrued liabilities | 21,511 | 8,285 | 4,603 | |||
| Debt | 16 | 18 | 296 | |||
| Other undisclosed current liabilities | 779 | 400 | ||||
| Total current liabilities: | 28,802 | 10,982 | 5,399 | |||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation | 2,118 | 269 | 512 | |||
| Finance lease, liability | 4 | 19 | ||||
| Liabilities, other than long-term debt | 2,345 | |||||
| Other liabilities | 2,345 | |||||
| Operating lease, liability | 2,114 | 250 | 512 | |||
| Other undisclosed noncurrent liabilities | 89,815 | (250) | ||||
| Total noncurrent liabilities: | 94,278 | 269 | 512 | |||
| Total liabilities: | 123,080 | 11,251 | 5,911 | |||
| Equity | ||||||
| Equity, attributable to parent | 99,537 | 186,659 | 137,298 | |||
| Common stock | 27 | 26 | 21 | |||
| Additional paid in capital | 354,920 | 341,384 | 221,508 | |||
| Accumulated deficit | (255,410) | (154,751) | (84,231) | |||
| Total equity: | 99,537 | 186,659 | 137,298 | |||
| TOTAL LIABILITIES AND EQUITY: | 222,617 | 197,910 | 143,209 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2022 TTM | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|
| Revenues | 24,539 | ||||
| Cost of revenue | (1,525) | ||||
| Provision for loan, lease, and other losses | (879) | ||||
| Gross profit: | 23,014 | ||||
| Operating expenses | (119,669) | (70,989) | (47,301) | ||
| Operating loss: | (96,655) | (70,989) | (47,301) | ||
| Nonoperating income (expense) | (4,004) | 469 | 1,590 | ||
| Investment income, nonoperating | 469 | 1,590 | |||
| Interest and debt expense | (3,734) | ||||
| Loss from continuing operations: | (104,393) | (70,520) | (45,711) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (104,393) | (70,520) | (45,711) | |
| Net loss: | (104,393) | (70,520) | (45,711) | ||
| Other undisclosed net income attributable to parent | 3,734 | ||||
| Net loss available to common stockholders, diluted: | (100,659) | (70,520) | (45,711) | ||
Comprehensive Income ($ in thousands)
| 9/30/2022 TTM | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|
| Net loss: | (104,393) | (70,520) | (45,711) | ||
| Comprehensive loss, net of tax, attributable to parent: | (104,393) | (70,520) | (45,711) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.